Antibody therapy developer Northern Biologics has extended its series A round and merged with oncology treatment developer Mosaic Biomedicals.
Northern Biologics, a Canada-based oncology and fibrosis-focused biotechnology company backed by pharmaceutical firm Celgene, merged with Spain-based personalised cancer therapy developer Mosaic Biomedicals on Monday.
Terms of the deal have not been disclosed. Venture capital firm Versant Ventures has concurrently extended its series A commitment to Northern Biologics by an undisclosed amount while Celgene exercised an option to acquire certain rights to the MSC-1 drug candidate.
The merger will support the development of MSC-1, an antibody Mosaic has created to…